India's BioServe Biotech Sells To Cancer Genetics For $1.9 Million
This article was originally published in PharmAsia News
Executive Summary
BioServe Biotechnologies in India has agreed to sell to Cancer Genetics for $1.9 million and become a wholly-owned subsidiary of the U.S. company.